Details
Minimal Residual Disease (MRD) testing is transforming cancer care, yet significant variability remains across technologies, indications, and clinical integration. This panel brings together experts from both industry and clinic to demystify MRD testing, discuss emerging best practices, and provide guidance on clinical and technical considerations.
The session will explore indication-specific requirements, the emerging value of whole genome sequencing (WGS)-based MRD approaches, and the evolving debate between tissue-informed and tissue-agnostic strategies. Attendees will gain practical insights into optimizing MRD testing workflows to enhance patient outcomes, while aligning with regulatory, scientific, and clinical standards.
Lauren C. Leiman
Executive Director and CEO
BLOODPAC
Jim Godsey, PhD
Scientific Co-Chair Committee
BLOODPAC
Traci Pawlowski, PhD
VP, Head Clinical Solutions
Illumina
Scientific Co-Chair Committee
BLOODPAC
Aparna R. Parikh, MD
Associate Professor, Medicine
Harvard Medical School
Oncologist
Massachusetts General Hospital Cancer Center
Jonathan Beer
Senior Director, Precision Medicine Lead
Bristol Myers Squibb
Get instant access to the webinar when it is available—just fill out this quick form.
Your email address is never shared with third parties.
- Date & Time
- 12 Nov. 2025
- Topic
- Oncology